Brokerages Set Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) PT at $25.00
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $25.00.
SNDX has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Guggenheim initiated coverage on shares of Syndax Pharmaceuticals in a research note on Friday. They issued a “buy” rating for the company.
Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 15.20 on Friday. The company’s market capitalization is $270.29 million. The company has a 50-day moving average price of $14.37 and a 200-day moving average price of $13.49. Syndax Pharmaceuticals has a one year low of $8.97 and a one year high of $18.03.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Analysts expect that Syndax Pharmaceuticals will post ($3.01) earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth about $100,000. Parametric Portfolio Associates LLC acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth about $229,000. State Street Corp acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth about $448,000. BlackRock Institutional Trust Company N.A. increased its position in shares of Syndax Pharmaceuticals by 6,091.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 43,216 shares of the company’s stock worth $426,000 after buying an additional 42,518 shares during the last quarter. Finally, BlackRock Fund Advisors acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth about $1,218,000. 57.64% of the stock is currently owned by institutional investors and hedge funds.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.